Stuelpnagel John R's Form 4 filing
10x Genomics, Inc. (TXG) · filed Dec 3, 2021
- Accession no.
- 0001567619-21-021614
- Filed
- Dec 3, 2021
- Trade date
- Dec 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $755.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stuelpnagel John RCIK 0001189140 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | Class A Common Stock | SSaleDisposed | −2,000 | $150.51F2 | −$301,020 | 349,616 | Direct | |
| Dec 1, 2021 | Class A Common Stock | SSaleDisposed | −1,700 | $151.10F3 | −$256,870 | 347,916 | Direct | |
| Dec 1, 2021 | Class A Common Stock | SSaleDisposed | −1,100 | $151.79F4 | −$166,969 | 346,816 | Direct | |
| Dec 1, 2021 | Class A Common Stock | SSaleDisposed | −100 | $154.02 | −$15,402 | 346,716 | Direct | |
| Dec 1, 2021 | Class A Common Stock | SSaleDisposed | −100 | $155.55 | −$15,555 | 346,616 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $150.00 to $150.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $151.00 to $151.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $151.53 to $152.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.